Hepion Pharmaceuticals, Inc. ( NASDAQ:HEPA – Free Report ) – Research analysts at Brookline Capital Management lowered their Q3 2023 earnings per share (EPS) estimates for Hepion Pharmaceuticals in a research report issued to clients and investors on Tuesday, October 3rd. Brookline Capital Management analyst K. Dolliver now anticipates that the company will earn ($2.68) per share for the quarter, down from their prior forecast of ($2.65). The consensus estimate for Hepion Pharmaceuticals' current full-year earnings is ($8.

https://www.dailypolitical.com/2023/10/07/research-analysts-set-expectations-for-hepion-pharmaceuticals-inc-s-q3-2023-earnings-nasdaqhepa.html

#dailypolitical